Atazanavir sulfate + cobicistat for the treatment of HIV infection

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Expert Review of Anti-Infective Therapy

• Publication date

  2017-05-09

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/14787210.2017.1323634PMID 28443391
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Report

  2019cited by this paper
• Less-drug regimen including atazanavir in maintenance treatment of HIV infection: how, who, when, why?

  2017cited by this paper
• Atazanavir Plus Cobicistat: Week 48 and Week 144 Subgroup Analyses of a Phase 3, Randomized, Double-Blind, Active-Controlled Trial§

  2017cited by this paper
• Atazanavir and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Patients: A Systematic Review

  2016cited by this paper
• Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel.

  2016cited by this paper
• Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications.

  2016influential reference
• Short Communication: High Viral Load and Multidrug Resistance Due to Late Switch to Second-Line Regimens Could Be a Major Obstacle to Reach the 90-90-90 UNAIDS Objectives in Sub-Saharan Africa.

  2016cited by this paper
• A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness

  2015cited by this paper
• Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.

  2015cited by this paper
• A Randomized Trial in Healthy Subjects to Assess the Bioequivalence of an Atazanavir/Cobicistat Fixed-Dose Combination Tablet versus Administration as Separate Agents

  2015cited by this paper
• Systematic Literature Review and Meta-Analysis of Renal Function in Human Immunodeficiency Virus (HIV)-Infected Patients Treated with Atazanavir (ATV)-Based Regimens

  2015cited by this paper
• Brief Report: Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate: Week 144 Results

  2015cited by this paper
• A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.

  2015cited by this paper
• Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.

  2015cited by this paper
• Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor–Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study

  2015cited by this paper
• Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).

  2014cited by this paper
• Tenofovir Alafenamide Vs. Tenofovir Disoproxil Fumarate in Single Tablet Regimens for Initial HIV-1 Therapy: A Randomized Phase 2 Study

  2014cited by this paper
• Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat

  2014cited by this paper
• Tenofovir Alafenamide is Not a Substrate for Renal Organic Anion Transporters (Oats) and Does Not Exhibit Oat-Dependent Cytotoxicity

  2014cited by this paper
• Pharmacokinetics of darunavir in fixed‐dose combination with cobicistat compared with coadministration of darunavir and ritonavir as single agents in healthy volunteers

  2014cited by this paper
• Cobicistat-Boosted Protease Inhibitors in HIV-Infected Patients with Mild to Moderate Renal Impairment

  2014cited by this paper
• An observational multi-cohort study on the use and safety of Combivir scored tablets among HIV-infected children and adolescents. Report to the European Medicines Agency (EMA)/ Committee for Medicinal Products for Human Use (CHMP)

  2014cited by this paper
• Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.

  2014influential reference
• Pharmacokinetics and Pharmacodynamics of Atazanavir‐containing Antiretroviral Regimens, with or without Ritonavir, in Patients who are HIV‐positive and Treatment‐naïve

  2013cited by this paper
• Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results.

  2013cited by this paper
• Atazanavir is not associated with an increased risk of cardio or cerebrovascular disease events

  2013cited by this paper
• Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir

  2012cited by this paper
• Effect of Cobicistat on Glomerular Filtration Rate in Subjects With Normal and Impaired Renal Function

  2012cited by this paper
• Metabolic Effects of Darunavir/Ritonavir Versus Atazanavir/Ritonavir in Treatment-Naive, HIV Type 1-Infected Subjects over 48 Weeks

  2012influential reference
• Scientific Considerations for Pharmacoenhancers in Antiretroviral Therapy

  2012cited by this paper
• Prevention of HIV-1 infection with early antiretroviral therapy

  2011cited by this paper
• Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.

  2011cited by this paper
• Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection

  2011cited by this paper
• The Bilirubin-Increasing Drug Atazanavir Improves Endothelial Function in Patients With Type 2 Diabetes Mellitus

  2011cited by this paper
• Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1

  2011cited by this paper
• Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study.

  2010cited by this paper
• Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trials.

  2010cited by this paper
• Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients

  2010cited by this paper
• Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4.

  2010cited by this paper
• Once-Daily Atazanavir/Ritonavir Compared With Twice-Daily Lopinavir/Ritonavir, Each in Combination With Tenofovir and Emtricitabine, for Management of Antiretroviral-Naive HIV-1–Infected Patients: 96-Week Efficacy and Safety Results of the CASTLE Study

  2010cited by this paper
• Pharmacokinetics and Bioavailability of an Integrase and Novel Pharmacoenhancer-Containing Single-Tablet Fixed-Dose Combination Regimen for the Treatment of HIV

  2010cited by this paper
• Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel Pharmacoenhancer.

  2010cited by this paper
• ON IN VITRO INVESTIGATION OF MITOCHONDRIAL TOXICITY OF ANTI-HIV NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS

  2008cited by this paper
• Ritonavir

  1998influential reference
• Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

  1997cited by this paper

• Current drugs for HIV-1: from challenges to potential in HIV/AIDS

  2023cites this paper
• A Combination of Novel HIV-1 Protease Inhibitor and Cytochrome P450 (CYP) Enzyme Inhibitor to Explore the Future Prospective of Antiviral Agents: Evotaz.

  2023cites this paper
• Improving Drug Delivery While Tailoring Prodrug Activation to Modulate Cmax and Cmin by Optimization of (Carbonyl)oxyalkyl Linker-Based Prodrugs of Atazanavir.

  2022cites this paper
• (Carbonyl)oxyalkyl linker-based amino acid prodrugs of the HIV-1 protease inhibitor atazanavir that enhance oral bioavailability and plasma trough concentration.

  2020cites this paper
• Modulating the Blood-Testis Barrier Towards Increasing Drug Delivery.

  2020cites this paper
• Epoxide Syntheses and Ring-Opening Reactions in Drug Development

  2020cites this paper
• Pharmacotherapeutic management of HIV in transplant patients

  2019cites this paper
• Association between the UGT1A1*28 allele and hyperbilirubinemia in HIV-positive patients receiving atazanavir: a meta-analysis

  2019cites this paper
• Structure of ScpC, a virulence protease from Streptococcus pyogenes, reveals the functional domains and maturation mechanism.

  2018cites this paper